Aclaris Therapeutics, Inc.
ACRS
$1.34
-$0.15-10.07%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -40.09% | 27.33% | 3.37% | 1.69% | 5.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -40.09% | 26.35% | 2.72% | 0.95% | 5.03% |
| Cost of Revenue | -57.32% | 40.08% | 20.09% | 45.03% | 73.78% |
| Gross Profit | 61.64% | -44.69% | -27.35% | -65.03% | -107.87% |
| SG&A Expenses | -29.54% | -21.63% | -13.52% | 6.26% | 25.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -51.12% | -37.27% | -18.09% | 3.51% | 26.85% |
| Operating Income | 54.13% | 49.04% | 24.29% | -4.34% | -34.47% |
| Income Before Tax | -48.64% | 67.40% | 43.93% | 19.37% | -2.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -49.26% | 67.72% | 44.28% | 19.75% | -1.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.26% | 67.72% | 44.28% | 19.75% | -1.81% |
| EBIT | 54.13% | 49.04% | 24.29% | -4.34% | -34.47% |
| EBITDA | 54.17% | 37.24% | 4.32% | -35.12% | -164.65% |
| EPS Basic | -18.68% | 68.82% | 46.78% | 24.53% | 4.26% |
| Normalized Basic EPS | 63.20% | 55.09% | 30.95% | 6.00% | -20.57% |
| EPS Diluted | -18.54% | 68.67% | 46.62% | 24.35% | 4.07% |
| Normalized Diluted EPS | 63.20% | 55.09% | 30.95% | 6.00% | -20.57% |
| Average Basic Shares Outstanding | 10.70% | 3.50% | 4.86% | 6.45% | 7.06% |
| Average Diluted Shares Outstanding | 10.70% | 3.50% | 4.86% | 6.45% | 7.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
